VNOVOTCWholesale-Apparel, Piece Goods & NotionsFiscal year ends April 30
VitaNova Life Sciences Corp
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$4.50+0.50 (+12.50%)
Close on Oct 19, 2026
- Market cap
- $37.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2026
Gross margin
30.1%
Operating margin
0.1%
Net margin
-1.2%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.7% | +330.2% | – | – | |
| Gross profit | -42.2% | +188.3% | – | – | |
| Operating income | -99.7% | – | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | 35.1% | -1.9% | |
| Return on assets | – | – | -1.6% | |
| Current ratio | – | 0.00 | 6.14 | |
| Inventory turnover | – | – | 28.2× | |
| Diluted shares | 1M | 2M | 8M |
Cash use needs five years of cash flow figures
VitaNova Life Sciences does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1.2%
×Asset turnover1.29×
×Equity multiplier1.19×
=Return on equity, FY2026-1.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -1.2% | 1.29× | 1.19× | -1.9% |
| FY2025 | 32.0% | 1.54× | 1.16× | 57.4% |
| FY2024 | 24.7% | 0.95× | 1.21× | 28.3% |
| FY2023 | -63.8% | 2.39× | -0.34× | 51.4% |
| FY2022 | 116.4% | 10.39× | -0.11× | -133.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$37.30K
- Cash generatingOperating cash flow above zero$814.41K
- Return on assets improvedROA up on the prior year71.3% → -1.7%
- Earnings backed by cashOperating cash flow above net income$814.41K vs -$37.30K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.49 → 6.14
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year59.19% → 30.10%
- More efficientAsset turnover rose2.23 → 1.34